<p>Marex Group plc 在第二季度购买了 Sana Biotechnology, Inc.（NASDAQ:SANA - 免费报告）的新股份，根据其最近向 SEC 提交的 13F 文件。这家机构投资者购买了 3,817,780 股该公司的股票，价值约为 10,423,000 美元。Marex Group plc 在最近一个季度末持有 Sana Biotechnology 约 1.61% 的股份。</p>
<ul>
<li>可能还有时间投资这三只热门生物科技股</li>
</ul>
<p>其他一些对冲基金也买卖了该公司的股票。Corient Private Wealth LLC 在第二季度将其在 Sana Biotechnology 的持股增加了 264.7%。Corient Private Wealth LLC 现在拥有 1,136,000 股该公司的股票，价值 3,101,000 美元，此前在此期间又购买了 824,505 股。Captrust Financial Advisors 在第二季度将其在 Sana Biotechnology 的持股增加了 43.8%。Captrust Financial Advisors 现在拥有 15,793 股该公司的股票，价值 43,000 美元，此前在上个季度又购买了 4,807 股。BNP Paribas Financial Markets 在第二季度将其在 Sana Biotechnology 的股份增加了 46.9%。BNP Paribas Financial Markets 现在拥有 15,444 股该公司的股票，价值 42,000 美元，此前在此期间又购买了 4,931 股。Brevan Howard Capital Management LP 在第二季度将其在 Sana Biotechnology 的持股增加了 85.3%。Brevan Howard Capital Management LP 现在拥有 260,723 股该公司的股票，价值 712,000 美元，此前在上个季度又购买了 120,016 股。最后，Adage Capital Partners GP L.L.C. 在第二季度以约 1,916,000 美元的价格购买了 Sana Biotechnology 的新股份。目前，88.23% 的股票由对冲基金和其他机构投资者持有。</p>
<p>获取 <strong>Sana Biotechnology</strong> 的提醒：</p>
<h2>Sana Biotechnology 价格表现</h2>
<p>SANA 股票在周五开盘价为 5.14 美元。该公司的 50 日简单移动平均线为 4.50 美元，200 日简单移动平均线为 3.76 美元。该股票的市值为 13.7 亿美元，市盈率为 -5.30，贝塔系数为 1.95。Sana Biotechnology, Inc. 的一年低点为 1.26 美元，一年高点为 7.30 美元。</p>
<p>Sana Biotechnology（NASDAQ:SANA - 获取免费报告）最近一次发布季度财报是在 11 月 6 日，报告每股收益（EPS）为 -0.15 美元，超出分析师一致预期的 -0.18 美元，超出幅度为 0.03 美元。研究分析师平均预计 Sana Biotechnology, Inc. 在当前财年将发布 -1.16 的每股收益。</p>
<h2>华尔街分析师观点</h2>
<p>几位股票研究分析师最近对该公司发表了看法。Weiss Ratings 在 12 月 8 日的研究报告中重申了对 Sana Biotechnology 股票的 &#34;卖出（d-）&#34; 评级。Citizens Jmp 在 10 月 30 日的研究报告中将 Sana Biotechnology 股票的目标价从 5.00 美元上调至 8.00 美元，并给予该公司 &#34;市场表现优于大盘&#34; 的评级。Wall Street Zen 在 11 月 22 日的研究报告中将 Sana Biotechnology 股票的评级从 &#34;持有&#34; 下调至 &#34;卖出&#34;。Wedbush 在 11 月 7 日的报告中将 Sana Biotechnology 股票的目标价从 5.00 美元上调至 6.00 美元，并给予该公司 &#34;表现优于大盘&#34; 的评级。最后，HC Wainwright 在 11 月 7 日的报告中将 Sana Biotechnology 股票的目标价从 11.00 美元下调至 9.00 美元，并对该股票给予 &#34;买入&#34; 评级。八位分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，该公司的平均评级为 &#34;适度买入&#34;，平均目标价为 8.33 美元。</p>
<p><strong>查看我们关于 Sana Biotechnology 的最新研究报告</strong></p>
<h2>Sana Biotechnology 公司简介</h2>
<p>（免费报告）</p>
<p>Sana Biotechnology, Inc. 是一家生物科技公司，专注于利用工程细胞作为药物。它开发了用于各种治疗领域的体外和体内细胞工程平台，以满足未满足的治疗需求，包括肿瘤学、糖尿病、中枢神经系统疾病、B 细胞介导的自身免疫等。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，而不是 Sana Biotechnology</li>
<li>使用 MarketBeat 股息收益计算器</li>
<li>迪士尼的 10 亿美元交易将其魔力带入 OpenAI</li>
<li>我在哪里可以找到 52 周高点和低点？</li>
<li>为什么亚马逊可能在几周内成为 300 美元的股票</li>
<li>资产配置：成功投资组合的关键。你在关注自己的投资组合吗？</li>
<li>Adobe 在财报后获得提振：长期前景看好</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0FOQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0FOQQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Sana Biotechnology 吗？</h2>
<p>在你考虑投资 Sana Biotechnology 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 Sana Biotechnology 并不在名单上。</p>
<p>虽然 Sana Biotechnology 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

SANA

<p>Marex Group plc 在第二季度购买了价值 1042 万美元的 Sana Biotechnology, Inc.的新股份，收购了 3,817,780 股。这项投资代表了对 Sana Biotechnology 约 1.61% 的持股比例。其他对冲基金也增加了在该公司的持仓。Sana Biotechnology 的股票在周五以 5.14 美元开盘，市值为 13.7 亿美元。分析师对该股票的评级不一，平均评级为 “适度买入”，平均目标价为 8.33 美元</p>

<p>Marex Group plc purchased a new stake in shares of Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 3,817,780 shares of the company's stock, valued at approximately $10,423,000. Marex Group plc owned approximately 1.61% of Sana Biotechnology at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Marex Group plc 在第二季度购买了 Sana Biotechnology, Inc.（NASDAQ:SANA - 免费报告）的新股份，根据其最近向 SEC 提交的 13F 文件。这家机构投资者购买了 3,817,780 股该公司的股票，价值约为 10,423,000 美元。Marex Group plc 在最近一个季度末持有 Sana Biotechnology 约 1.61% 的股份。</p>
</div><ul>
<li>There May Still Be Time to Get in on These 3 Trending Biotechs</li>
</ul>
<div class="lb-trans"><ul>
<li>可能还有时间投资这三只热门生物科技股</li>
</ul>
</div><p>A number of other hedge funds have also bought and sold shares of the business. Corient Private Wealth LLC raised its holdings in Sana Biotechnology by 264.7% during the 2nd quarter. Corient Private Wealth LLC now owns 1,136,000 shares of the company's stock valued at $3,101,000 after acquiring an additional 824,505 shares during the period. Captrust Financial Advisors grew its position in shares of Sana Biotechnology by 43.8% in the second quarter. Captrust Financial Advisors now owns 15,793 shares of the company's stock valued at $43,000 after purchasing an additional 4,807 shares in the last quarter. BNP Paribas Financial Markets raised its stake in shares of Sana Biotechnology by 46.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 15,444 shares of the company's stock valued at $42,000 after purchasing an additional 4,931 shares during the period. Brevan Howard Capital Management LP lifted its holdings in Sana Biotechnology by 85.3% during the 2nd quarter. Brevan Howard Capital Management LP now owns 260,723 shares of the company's stock worth $712,000 after purchasing an additional 120,016 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. bought a new position in Sana Biotechnology in the 2nd quarter worth about $1,916,000. 88.23% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他一些对冲基金也买卖了该公司的股票。Corient Private Wealth LLC 在第二季度将其在 Sana Biotechnology 的持股增加了 264.7%。Corient Private Wealth LLC 现在拥有 1,136,000 股该公司的股票，价值 3,101,000 美元，此前在此期间又购买了 824,505 股。Captrust Financial Advisors 在第二季度将其在 Sana Biotechnology 的持股增加了 43.8%。Captrust Financial Advisors 现在拥有 15,793 股该公司的股票，价值 43,000 美元，此前在上个季度又购买了 4,807 股。BNP Paribas Financial Markets 在第二季度将其在 Sana Biotechnology 的股份增加了 46.9%。BNP Paribas Financial Markets 现在拥有 15,444 股该公司的股票，价值 42,000 美元，此前在此期间又购买了 4,931 股。Brevan Howard Capital Management LP 在第二季度将其在 Sana Biotechnology 的持股增加了 85.3%。Brevan Howard Capital Management LP 现在拥有 260,723 股该公司的股票，价值 712,000 美元，此前在上个季度又购买了 120,016 股。最后，Adage Capital Partners GP L.L.C. 在第二季度以约 1,916,000 美元的价格购买了 Sana Biotechnology 的新股份。目前，88.23% 的股票由对冲基金和其他机构投资者持有。</p>
</div><p>Get <strong>Sana Biotechnology</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Sana Biotechnology</strong> 的提醒：</p>
</div><h2>Sana Biotechnology Price Performance</h2>
<div class="lb-trans"><h2>Sana Biotechnology 价格表现</h2>
</div><p>SANA stock opened at $5.14 on Friday. The firm has a 50 day simple moving average of $4.50 and a two-hundred day simple moving average of $3.76. The stock has a market cap of $1.37 billion, a PE ratio of -5.30 and a beta of 1.95. Sana Biotechnology, Inc. has a one year low of $1.26 and a one year high of $7.30.</p>
<div class="lb-trans"><p>SANA 股票在周五开盘价为 5.14 美元。该公司的 50 日简单移动平均线为 4.50 美元，200 日简单移动平均线为 3.76 美元。该股票的市值为 13.7 亿美元，市盈率为 -5.30，贝塔系数为 1.95。Sana Biotechnology, Inc. 的一年低点为 1.26 美元，一年高点为 7.30 美元。</p>
</div><p>Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.18) by $0.03. On average, research analysts expect that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Sana Biotechnology（NASDAQ:SANA - 获取免费报告）最近一次发布季度财报是在 11 月 6 日，报告每股收益（EPS）为 -0.15 美元，超出分析师一致预期的 -0.18 美元，超出幅度为 0.03 美元。研究分析师平均预计 Sana Biotechnology, Inc. 在当前财年将发布 -1.16 的每股收益。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several equities research analysts have recently weighed in on the company. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Sana Biotechnology in a research report on Monday, December 8th. Citizens Jmp boosted their price objective on shares of Sana Biotechnology from $5.00 to $8.00 and gave the company a &#34;market outperform&#34; rating in a research note on Thursday, October 30th. Wall Street Zen cut shares of Sana Biotechnology from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday, November 22nd. Wedbush raised their price target on shares of Sana Biotechnology from $5.00 to $6.00 and gave the company an &#34;outperform&#34; rating in a report on Friday, November 7th. Finally, HC Wainwright decreased their price target on shares of Sana Biotechnology from $11.00 to $9.00 and set a &#34;buy&#34; rating on the stock in a report on Friday, November 7th. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of &#34;Moderate Buy&#34; and an average price target of $8.33.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对该公司发表了看法。Weiss Ratings 在 12 月 8 日的研究报告中重申了对 Sana Biotechnology 股票的 &#34;卖出（d-）&#34; 评级。Citizens Jmp 在 10 月 30 日的研究报告中将 Sana Biotechnology 股票的目标价从 5.00 美元上调至 8.00 美元，并给予该公司 &#34;市场表现优于大盘&#34; 的评级。Wall Street Zen 在 11 月 22 日的研究报告中将 Sana Biotechnology 股票的评级从 &#34;持有&#34; 下调至 &#34;卖出&#34;。Wedbush 在 11 月 7 日的报告中将 Sana Biotechnology 股票的目标价从 5.00 美元上调至 6.00 美元，并给予该公司 &#34;表现优于大盘&#34; 的评级。最后，HC Wainwright 在 11 月 7 日的报告中将 Sana Biotechnology 股票的目标价从 11.00 美元下调至 9.00 美元，并对该股票给予 &#34;买入&#34; 评级。八位分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，该公司的平均评级为 &#34;适度买入&#34;，平均目标价为 8.33 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on Sana Biotechnology</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Sana Biotechnology 的最新研究报告</strong></p>
</div><h2>Sana Biotechnology Profile</h2>
<div class="lb-trans"><h2>Sana Biotechnology 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.</p>
<div class="lb-trans"><p>Sana Biotechnology, Inc. 是一家生物科技公司，专注于利用工程细胞作为药物。它开发了用于各种治疗领域的体外和体内细胞工程平台，以满足未满足的治疗需求，包括肿瘤学、糖尿病、中枢神经系统疾病、B 细胞介导的自身免疫等。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Sana Biotechnology</li>
<li>Using the MarketBeat Dividend Yield Calculator</li>
<li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li>
<li>Where Do I Find 52-Week Highs and Lows?</li>
<li>Why Amazon Could Be a $300 Stock Within Weeks</li>
<li>Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?</li>
<li>Adobe Gets Post-Earnings Lift: Long-Term Outlook Favors Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，而不是 Sana Biotechnology</li>
<li>使用 MarketBeat 股息收益计算器</li>
<li>迪士尼的 10 亿美元交易将其魔力带入 OpenAI</li>
<li>我在哪里可以找到 52 周高点和低点？</li>
<li>为什么亚马逊可能在几周内成为 300 美元的股票</li>
<li>资产配置：成功投资组合的关键。你在关注自己的投资组合吗？</li>
<li>Adobe 在财报后获得提振：长期前景看好</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0FOQQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=SANA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Sana Biotechnology Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Sana Biotechnology 吗？</h2>
</div><p>Before you consider Sana Biotechnology, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Sana Biotechnology 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sana Biotechnology wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 Sana Biotechnology 并不在名单上。</p>
</div><p>While Sana Biotechnology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Sana Biotechnology 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Marex Group plc 在 Sana Biotechnology, Inc. $SANA 中建立了价值 1042 万美元的头寸